ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/aromatase-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/aromatase-inhibitor
18
trial(s) found.
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NA
4215 - Southport - Icon Cancer Centre Southport
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06465368
Curative
Phase 2
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING (
C4391025
)
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06120283
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (
BGB-43395-101
)
CDK4 selective inhibitor
+ aromatase inhibitor
Breast cancer
Cancer
HER2-negative breast cancer
HR-positive breast cancer
Non-small cell lung cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2576 - Bowral - Southern Highlands Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
+ aromatase inhibitor
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
+ aromatase inhibitor
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
+ aromatase inhibitor
Breast cancer
Endometrial cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05827081
Curative
Phase 3
Not yet recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
+ aromatase inhibitor
Breast cancer
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
NCT05774951
Curative
Phase 3
Recruiting
CAMBRIA-1
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
selective estrogen receptor degrader
selective estrogen receptor modulator
+ aromatase inhibitor
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT05514054
Curative
Phase 3
Recruiting
EMBER-4
: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4215 - Southport - Gold Coast University Hospital
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT04606446
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors. (
KAT6
)
KAT6 inhibitor
+ aromatase inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ aromatase inhibitor
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ aromatase inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
+ aromatase inhibitor
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06105632
Advanced
Phase 2
Active not recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1) (
C4391022
)
CDK4 selective inhibitor
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06016738
Advanced
Phase 3
Active not recruiting
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (
OPERA-01
)
complete estrogen receptor antagonist
+ aromatase inhibitor
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
3630 - Shepparton - Goulburn Valley Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05909397
Advanced
Phase 3
Active not recruiting
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (
VERITAC-3
)
CDK4/6 inhibitor
ER PROTAC degrader
aromatase inhibitor
Breast cancer
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05307705
Advanced
Phase 1
Active not recruiting
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation (
PIKASSO-01
)
PI3Kalpha H1047R inhibitor
+ aromatase inhibitor
Breast cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Active not recruiting (4)
Not yet recruiting (1)
Recruitment Country and State
NSW (15)
VIC (14)
SA (10)
QLD (8)
WA (8)
NZ (4)
TAS (3)
ACT (1)
NT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (2)
Phase 2 (3)
Phase 3 (9)
Trial Type
Advanced (12)
Curative (6)
Cancer Therapy Class
oestrogen axis
100%
ER
67%
CDK4
67%
CDK6
50%
CDK4 selective
22%
PARP
11%
Trop2
11%
androgen axis
11%
PI3Kalpha
11%
VEGF
11%
PARP1-selective
6%
BRAF
6%
CRAF
6%
FAK
6%
MEK
6%
RAF
6%
pan-RAF
6%
CDK2
6%
GnRH
6%
KAT6
6%
AKT
6%
CD40
6%
ERBB2
6%
IL-6
6%
LIV1
6%
PD-1/PD-L1
6%
PD-L1
6%
AR
6%
CYP17A1
6%
HMG-CoA reductase
6%
mTOR
6%
mTORC1
6%
ER
6%
PI3Kalpha H1047R
6%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
2031 - Randwick - Prince of Wales Hospital (5)
3630 - Shepparton - Goulburn Valley Health (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
3168 - Clayton - Monash Medical Centre (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
2500 - Wollongong - Wollongong Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2485 - Tweed Heads - The Tweed Hospital (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
7000 - Hobart - Royal Hobart Hospital (2)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
4215 - Southport - Icon Cancer Centre Southport
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2576 - Bowral - Southern Highlands Private Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2060 - North Sydney - Mater Hospital (1)
3066 - Epping - Northern Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3135 - Ringwood East - Maroondah Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Breast adenocarcinoma
Epithelial Ovarian Cancer
Gynaecological cancer
Ovarian cancer
HER2-negative breast cancer
HR-positive breast cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Endometrial cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
Peritoneal cancer
Primary peritoneal serous carcinoma
Triple-negative breast cancer
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Urogenital cancer
Carcinoma
Endometrial stromal sarcoma
High-grade serous ovarian cancer
Leiomyosarcoma
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Sarcoma
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
ER-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy